Read by QxMD icon Read

Journal of Crohn's & Colitis

Anne Dumay, Olivier Gergaud, Maryline Roy, Jean-Pierre Hugot
BACKGROUND AND AIMS: Nucleotide Oligomerisation Domain 2 (NOD2) is a key gene of innate immunity which participates to the host defence toward pathogens. Several loss-of-function NOD2 mutations are associated with Crohn Disease (CD). Their high frequencies in populations of European ancestry suggest a model of balancing selection. Because NOD2 deficiency has been associated with a resistance to Yersinia pseudotuberculosis in mice we hypothesized that NOD2 mutations have been selected during past plague outbreaks due to the closely related bacteria Yersinia pestis...
March 20, 2019: Journal of Crohn's & Colitis
Kristian Bolin, Erik Hertervig, Edouard Louis
OBJECTIVES: to examine the cost-effectiveness of continued treatment for patients with moderate-severe Crohn's disease in clinical remission, with a combination of anti-TNFα (infliximab) and immunomodulator therapy compared to two different withdrawal strategies (1) withdrawal of the anti-TNFα therapy, and (2) withdrawal of the immunomodulator therapy, respectively. MATERIAL AND METHODS: A decision-tree model was constructed mimicking three treatment arms: (1) continued combination therapy with infliximab and immunomodulator, (2) withdrawal of infliximab, or (3) withdrawal of the immunomodulator...
March 20, 2019: Journal of Crohn's & Colitis
Huanyu Zhou, Li Xi, Daniel Ziemek, Shawn O'Neil, Julie Lee, Zachary Stewart, Yutian Zhan, Shanrong Zhao, Ying Zhang, Karen Page, Austin Huang, Mateusz Maciejewski, Baohong Zhang, Kenneth J Gorelick, Lori Fitz, Vivek Pradhan, Fabio Cataldi, Michael Vincent, David Von Schack, Kenneth Hung, Mina Hassan-Zahraee
BACKGROUND AND AIMS: To define pharmacodynamic and efficacy biomarkers in ulcerative colitis [UC] patients treated with PF-00547659, an anti-human mucosal addressin cell adhesion molecule-1 [MAdCAM-1] monoclonal antibody, in the TURANDOT study. METHODS: Transcriptome, proteome and immunohistochemistry data were generated in peripheral blood and intestinal biopsies from 357 subjects in the TURANDOT study. RESULTS: In peripheral blood, C-C motif chemokine receptor 9 [CCR9] gene expression demonstrated a dose-dependent increase relative to placebo, but in inflamed intestinal biopsies CCR9 gene expression decreased with increasing PF-00547659 dose...
March 19, 2019: Journal of Crohn's & Colitis
Nienke Z Borren, Jay Luther, Francis P Colizzo, John G Garber, Hamed Khalili, Ashwin N Ananthakrishnan
BACKGROUND AND AIMS: Methotrexate [MTX] is a well-known immunomodulator in the treatment of inflammatory bowel disease [IBD] and is often combined with biologic agents. The ideal MTX dose for combination therapy has not been determined. This study aimed to investigate the effect of varying doses of MTX on efficacy and safety outcomes when used with anti-TNF agents in IBD. METHODS: This study included patients with Crohn's disease [CD] or ulcerative colitis [UC] receiving care between January 2005 and June 2018...
March 19, 2019: Journal of Crohn's & Colitis
Alka A Potdar, Dalin Li, Talin Haritunians, Kelli L VanDussen, Marie F Fiorino, Ta-Chiang Liu, Thaddeus S Stappenbeck, Phillip Fleshner, Stephan R Targan, Dermot P B McGovern, Janine Bilsborough
BACKGROUND AND AIMS: Heterogeneity in Crohn's disease (CD) provides a challenge for development of effective therapies. Our goal was to define a unique molecular signature for severe, refractory CD to enable precision therapy approaches to disease treatment and facilitate earlier intervention in complicated disease. METHODS: We analyzed clinical meta-data, genetics and transcriptomics from uninvolved ileal tissue from CD patients that underwent a single SB resection...
March 16, 2019: Journal of Crohn's & Colitis
Simone Y Loo, Maria Vutcovici, Alain Bitton, Peter L Lakatos, Laurent Azoulay, Samy Suissa, Paul Brassard
OBJECTIVES: To explore the trends and the predictors of incident malignant cancer among patients with inflammatory bowel disease (IBD). METHODS: We identified a cohort of all patients with incident IBD in Quebec, Canada, from 1998 to 2015, using provincial administrative healthcare databases (RAMQ and Med-Echo). Annual incidence rates (IRs) of cancer were calculated using Poisson regression and were compared to the Quebec population using standardized incidence ratios (SIR)...
March 15, 2019: Journal of Crohn's & Colitis
Wolfgang Kruis, Phuong Nguyen, Julia Morgenstern, Wolfgang Ramlow, Axel Dignaß, Andreas Stallmach, Uta Drebber
BACKGROUND AND AIMS: In active ulcerative colitis [UC] refractory to mesalazine, escalation to either steroids or immunosuppression is common practice. The efficacy and safety of alternative escalation therapy with a novel leukocyte apheresis device were studied. METHODS: This was a prospective, randomized, controlled multicentre pilot study comparing leukocyte apheresis with prednisolone in refractory UC (disease activity index [DAI] ≥ 4 and ≤8). Group A received weekly apheresis over five consecutive weeks...
March 13, 2019: Journal of Crohn's & Colitis
Anna Rawa-Gołębiewska, Małgorzata Lenarcik, Edyta Zagórowicz
No abstract text is available yet for this article.
March 12, 2019: Journal of Crohn's & Colitis
Ajit Sood, Ramit Mahajan, Arshdeep Singh, Vandana Midha, Varun Mehta, Vikram Narang, Tarundeep Singh, Anmol Singh Pannu
OBJECTIVES: To study the role of fecal microbiota transplantation (FMT) in maintenance of remission in ulcerative colitis (UC). METHODS: In this pilot study, patients with UC in clinical remission after multi-session FMT were randomly allocated to either maintenance FMT or placebo colonoscopic infusion every 8 weeks, for 48 weeks. The standard of care (SOC) therapy was continued in all patients. The primary end point was maintenance of steroid-free clinical remission (Mayo score ≤2, all sub scores ≤ 1) at week 48...
March 11, 2019: Journal of Crohn's & Colitis
Jera Jeruc, David Drobne, Nina Zidar
No abstract text is available yet for this article.
March 11, 2019: Journal of Crohn's & Colitis
Masoumeh Azimirad, Abbas Yadegar, Hamid Asadzadeh Aghdaei, Colleen R Kelly
No abstract text is available yet for this article.
March 10, 2019: Journal of Crohn's & Colitis
Laurie Keefer
No abstract text is available yet for this article.
March 9, 2019: Journal of Crohn's & Colitis
Roy Frei, Nicolas Fournier, Jonas Zeitz, Michael Scharl, Bernhard Morell, Thomas Greuter, Philipp Schreiner, Benjamin Misselwitz, Ekaterina Safroneeva, Alain M Schoepfer, Stephan R Vavricka, Gerhard Rogler, Luc Biedermann
BACKGROUND AND AIMS: The optimal timing of treatment escalation in Crohn's disease (CD) remains a challenge and very little is known about its long-term development following early versus late administration of anti-TNF antibodies. The long-term outcome of Swiss CD patients was comparatively assessed in an up to 10-year follow-up, using patients participating in the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). METHODS: Prospectively-collected SIBDCS patient data, including disease history, baseline characteristics at enrolment and course of disease were analysed in patients with early versus late (<24 versus >=24 months after diagnosis) and no anti-TNF treatment...
March 7, 2019: Journal of Crohn's & Colitis
George Philip, Freddy Cornillie, J Omoniyi Adedokun, Richard Melsheimer, Paul Rutgeerts, Jean-Frederic Colombel, Colleen Marano
BACKGROUND AND AIMS: In nonresponders to golimumab induction for ulcerative colitis, we assessed clinical response rates and golimumab serum concentrations when the 100 mg dose is used early in the course of maintenance.Methods: This post-hoc analysis of golimumab maintenance dosing (in the PURSUIT-M study) examined clinical outcomes and golimumab concentrations in early (Week 6) responders and nonresponders to induction, including subgroups based on body weight. RESULTS: In nonresponders to golimumab induction (assessed at Week 6), the 100 mg maintenance dose (starting at Week 6) resulted in a meaningful proportion (28...
March 7, 2019: Journal of Crohn's & Colitis
Frederik R Pachler, Gunnar Toft, Thue Bisgaard, Søren Laurberg
BACKGROUND AND AIMS: Fertility decreases in women following restorative proctocolectomy for ulcerative colitis. The use and success of in vitro fertilization after restorative proctocolectomy for ulcerative colitis is not systematically studied.We aimed to estimate the use and success of in vitro fertilization treatment in female ulcerative colitis patients, with and without restorative proctocolectomy. METHODS: Women of fertile age (15-49 years) with restorative proctocolectomy for ulcerative colitis were compared with females with ulcerative colitis without restorative proctocolectomy...
March 6, 2019: Journal of Crohn's & Colitis
Hadar Moran-Lev, Tut Galai, Anat Yerushalmy-Feler, Yosef Weisman, Adi Anafi, Varda Deutsch, Michal Cipok, Ronit Lubetzky, Shlomi Cohen
BACKGROUND AND AIMS: The role of hepcidin in inflammatory bowel disease (IBD) children with anemia is poorly understood. However, it has been shown that vitamin D suppresses hepcidin expression. We aimed to assess serum hepcidin levels and the effect of vitamin D treatment on those levels in newly diagnosed IBD pediatric patients. METHODS: Eighty-five children were prospectively recruited in the Dana-Dwek Children's Hospital (40 newly diagnosed IBD, 45 healthy controls, 47% female, mean age 13...
March 6, 2019: Journal of Crohn's & Colitis
L Godny, N Maharshak, L Reshef, I Goren, L Yahav, N Fliss-Isakov, U Gophna, H Tulchinsky, I Dotan
BACKGROUND: Patients with ulcerative colitis (UC) that undergo proctocolectomy with an ileal pouch-anal anastomosis commonly develop pouch inflammation (pouchitis). Pouchitis develops in a previously normal small intestine and may involve environmental factors. We explored whether diet and microbiota alterations contributed to the pathogenesis of pouchitis. METHODS: Patients were recruited and prospectively followed at a comprehensive pouch clinic. Pouch behavior was clinically defined as a normal pouch (NP) or pouchitis...
March 4, 2019: Journal of Crohn's & Colitis
Niels Vande Casteele, Filip Baert, Sumin Bian, Erwin Dreesen, Griet Compernolle, Gert Van Assche, Marc Ferrante, Severine Vermeire, Ann Gils
BACKGROUND: Therapeutic drug monitoring is used to optimize adalimumab therapy in patients with Crohn's disease (CD). However, the interindividual variability in drug absorption and the quantitative effect on drug clearance of antiadalimumab antibodies (AAA), measured with a drug resistant assay, is unclear. AIM: Characterize adalimumab population pharmacokinetics (PopPK) and identify determinants of interindividual variability in patients with CD. METHODS: Prospective multicentre open-label cohort study in 28 patients with CD starting adalimumab therapy...
March 1, 2019: Journal of Crohn's & Colitis
Joana Torres, Pierre Ellul, Jost Langhorst, Antonina Mikocka-Walus, Manuel Barreiro-de Acosta, Chamara Basnayake, Nik John Sheng Ding, Daniela Gilardi, Konstantinos Katsanos, Gabriele Moser, Randi Opheim, Carolina Palmela, Gianluca Pellino, Sander Van der Marel, Stephan R Vavricka
Patients with Inflammatory Bowel Disease increasingly use alternative and complementary therapies, for which appropriate evidence is often lacking. It is estimated that up to half of all patients with IBD use various forms of complementary and alternative medicine during some point in their disease course. Considering the frequent use of such therapies, it is crucial that physicians and patients are informed about their efficacy and safety in order to provide guidance and evidence-based advice. Additionally, increasing evidence suggests that some psychotherapies and mind-body interventions may be beneficial in the management of IBD, but their best use remains a matter of research...
March 1, 2019: Journal of Crohn's & Colitis
Gianluca Galazzo, Danyta I Tedjo, Dion S J Wintjens, Paul H M Savelkoul, Ad A M Masclee, Alexander G L Bodelier, Marie J Pierik, John Penders, Daisy M A E Jonkers
BACKGROUND: Microbial shifts have been associated with disease activity in Crohn's disease (CD), but findings on specific taxa are inconsistent. This may be due to differences in applied methods and cross-sectional study designs. We prospectively examined the fecal microbiota in adult CD patients with changing or stable disease course over time. METHODS: Feces was collected at two time-points from 15 healthy individuals (HC), 35 CD patients that maintained remission (RR) and 22 during remission and subsequent exacerbation (RA)...
February 27, 2019: Journal of Crohn's & Colitis
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"